| 3.03 -0.28 (-8.46%) | 11-21 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.47  |
1-year : | 5.08 |
| Resists | First : | 3.83 |
Second : | 4.34 |
| Pivot price | 3.64 |
|||
| Supports | First : | 3 |
Second : | 2.49 |
| MAs | MA(5) : | 3.27 |
MA(20) : | 3.75 |
| MA(100) : | 4.61 |
MA(250) : | 0 | |
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 9.7  |
D(3) : | 12.3 |
| RSI | RSI(14): 28.9 |
|||
| 52-week | High : | 7.76 | Low : | 3 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CJMB ] has closed above bottom band by 2.8%. Bollinger Bands are 67.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.55 - 3.57 | 3.57 - 3.59 |
| Low: | 2.96 - 2.98 | 2.98 - 3 |
| Close: | 3 - 3.03 | 3.03 - 3.06 |
Callan JMB Inc., through its subsidiary, Coldchain Technology Services, LLC provides thermal management logistics solutions to the life sciences industry. It offers logistics solutions and services utilized for frozen shipping in the life sciences industry, including personalized medicine, cell therapies, stem cells, cell lines, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, organs, biopharmaceuticals, infectious substances, and other commodities. The company also provides perishable (non-pharma) client packaging, and technical services. The company was founded in 2006 and is headquartered in Spring Branch, Texas.
Fri, 14 Nov 2025
Callan JMB Inc. Expands Logistics Platform and Advances Strategic Growth Initiatives Across Multiple Sectors - Quiver Quantitative
Fri, 14 Nov 2025
Callan JMB Announces Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Fri, 14 Nov 2025
Callan JMB Insiders Lose Out As Stock Sinks To US$3.44 - simplywall.st
Thu, 13 Nov 2025
Callan JMB Enters Agreement to Install Oral Drug Delivery Equipment in Texas Facility - GlobeNewswire
Thu, 13 Nov 2025
Callan JMB Inc. Enters Agreement to Install Oral Drug Delivery Equipment in Texas Facility - MarketScreener
Mon, 10 Nov 2025
EXCLUSIVE: Callan JMB Teams Up With Keychain To Boost Food Sampling Compliance Services - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Industrials
|
|
|
Industry:
Integrated Freight & Logistics
|
|
| Shares Out | 4 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 71.6 (%) |
| Held by Institutions | 16.8 (%) |
| Shares Short | 11 (K) |
| Shares Short P.Month | 6 (K) |
| EPS | -1.06 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.29 |
| Profit Margin | -80.4 % |
| Operating Margin | -84.2 % |
| Return on Assets (ttm) | -36.7 % |
| Return on Equity (ttm) | -85.9 % |
| Qtrly Rev. Growth | -16.2 % |
| Gross Profit (p.s.) | 0.47 |
| Sales Per Share | 1.31 |
| EBITDA (p.s.) | -1.02 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -2 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -2.86 |
| PEG Ratio | 0 |
| Price to Book value | 2.33 |
| Price to Sales | 2.3 |
| Price to Cash Flow | -7.3 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|